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Background: Tenascins are large glycoproteins found in the extracellular matrix of many embryonic and adult
tissues. Tenascin-C is a well-studied biomarker known for its high overexpression in the stroma of most solid
cancers. Tenascin-W, the least studied member of the family, is highly expressed in the stroma of colon and breast
tumors and in gliomas, but not in the corresponding normal tissues. Other solid tumors have not been analyzed.
The present study was undertaken to determine whether tenascin-W could serve as a cancer-specific extracellular
matrix protein in a broad range of solid tumors.
Methods: We analyzed the expression of tenascin-W and tenascin-C by immunoblotting and by
immunohistochemistry on multiple frozen tissue microarrays of carcinomas of the pancreas, kidney and lung as well
as melanomas and compared them to healthy tissues.
Results: From all healthy adult organs tested, only liver and spleen showed detectable levels of tenascin-W,
suggesting that tenascin-W is absent from most human adult organs under normal, non-pathological conditions. In
contrast, tenascin-W was detectable in the majority of melanomas and their metastases, as well as in pancreas,
kidney, and lung carcinomas. Comparing lung tumor samples and matching control tissues for each patient
revealed a clear overexpression of tenascin-W in tumor tissues. Although the number of samples examined is too
small to draw statistically significant conclusions, there seems to be a tendency for increased tenascin-W expression
in higher grade tumors. Interestingly, in most tumor types, tenascin-W is also expressed in close proximity to blood
vessels, as shown by CD31 co-staining of the samples.
Conclusions: The present study extends the tumor biomarker potential of tenascin-W to a broad range of solid
tumors and shows its accessibility from the blood stream for potential therapeutic strategies.Background
During recent years increasing evidence has emerged
showing that the microenvironment plays a prominent
role in determining tumor behavior [1-4]. Tumor pro-
gression is influenced and controlled by activation of
nearby stromal cells, including fibroblasts, endothelial
cells and macrophages. In their activated states, these
cells modulate and reorganize the extracellular matrix
and create a congenial microenvironment for the tumor
cells. Accepting an active role of the microenvironment* Correspondence: ruth.chiquet@fmi.ch
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reproduction in any medium, provided the orfor tumor progression, it will be important to consider
how the activated tumor stroma can be harnessed for
clinical benefit. Extracellular matrix proteins specifically
expressed in the tumor stroma could thus represent
promising predictive/diagnostic biomarkers or target
molecules for therapeutics.
Tenascin-C (TNC) and tenascin-W (TNW) are two
members of the tenascin family of large extracellular
matrix glycoproteins (see [5] for information on the
structure of tenascins). Their functions are associated
with cellular mechanisms such as adhesion modulation,
motility, proliferation and differentiation [5]. Both pro-
teins share highest expression during embryonic devel-
opment and reduced and very restricted expression in
adult tissues [6]. TNC, the best-described family mem-
ber, reappears during pathological conditions such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its initial identification, TNC was proposed as a stromal
marker in breast cancer [9]. Since then, many more
studies shown that TNC expression could have predict-
ive value for local tumor recurrence and metastatic dis-
semination in many aggressive cancers (for reviews see
[2,10,11]. Its cancer-specific expression has been
exploited to make TNC a promising target for different
anti-cancer therapies, including the delivery of cytokines
or radionuclides to the tumor using TNC-specific mono-
clonal antibodies [12-14] or aptamers [15,16].
Similar physiological expression patterns as well as
shared functions of TNW with TNC prompted us to in-
vestigate the presence of the newest tenascin family
member, TNW in different human cancers. TNW ex-
pression was detected in a large majority of human
breast tumors, showing enrichment in low-grade com-
pared to high-grade tumors [17]. In colorectal cancer,
TNW expression was restricted to the tumor-associated
microenvironment, while the protein was not detectable
in the corresponding healthy tissue [18]. In brain
tumors, all glioma subtypes tested (oligodendroglioma,
astrocytoma and glioblastoma) were enriched in TNW
in comparison to healthy control brain tissues [19]. No-
ticeably, in all glioblastoma samples analyzed the
localization of TNW was perivascular [19].
Encouraged by the highly tumor-specific expression of
TNW in breast, colon, and brain tumors, we now
extended our expression study to many more types of
solid tumors. We show here, that TNW expression dis-
plays an even higher specificity for cancer-related micro-
environments than TNC. Hence, TNW represents a
novel attractive cancer biomarker of broad potential for
tumor detection, prediction and targeting approaches.
Methods
Tissue samples
Protein extracts from uterus, spleen, liver, lung, cere-
brum and heart control tissues were from autoptic ma-
terial obtained from the Institute of Pathology from the
University Hospital of Basel, Switzerland. Pancreas, kid-
ney and colon control whole tissue homogenates were
purchased from BioCat GmbH (Heidelberg, Germany).
Protein extracts from breast, pancreas and kidney
tumors were obtained from the Institute of Pathology of
the University Hospital of Basel, Switzerland. All extracts
were prepared as described before [17].
Melanomas, kidney and lung tumors used for immu-
nohistochemistry were part of frozen tissue microarrays
(TMA) obtained from the Institute of Pathology of the
University Hospital of Basel, Switzerland. References for
their construction can be found elsewhere [17]. The
melanoma TMA was constructed from frozen tissue
samples of 34 malignant melanomas (5 primary tumors,8 metastases from different organs and 21 lymph node
metastases) and 6 control healthy cutaneous tissue sam-
ples. The kidney TMA was constructed from frozen tis-
sue samples of 84 kidney tumors (70 clear cell renal
carcinomas, 6 papillary renal carcinomas, 6 chromo-
phobe renal cell carcinomas and 2 oncocytoma) and 10
healthy control kidney tissues. The lung TMA was con-
structed from frozen tissue samples of 74 lung tumors
(40 squamous carcinomas, 19 adenocarcinomas and 15
undifferentiated carcinomas). Additional lung tumor
samples were obtained from the University Hospital of
Tours, France. The latter collection contained frozen tis-
sues from matched samples of tumor and adjacent non-
tumor tissue. They were obtained from 21 patients who
had undergone lung cancer resection as their primary
therapy without preoperative radiation or chemotherapy.
These non-small cell lung cancers consisted of 10
adenocarcinomas, 10 squamous carcinomas and 1 undif-
ferentiated carcinoma. The non-malignant tissue sam-
ples were taken from sites at least 3 cm away from the
edge of the tumor. The histological diagnosis was deter-
mined by two pathologists.
Studies were performed in compliance with the Dec-
laration of Helsinki and in accordance with the guide-
lines of the ethical committee of the University of Basel,
Switzerland or with French bioethical regulations.
Western blot analysis
Tissue samples were thawed on ice, minced and homoge-
nized in RIPA lysis buffer. After determination of protein
concentration by a Bio-Rad Protein assay, 25 μg of pro-
tein were separated by SDS-PAGE (6%) and electro-
blotted to polyvinylidene difluoride membranes. Equal
loading and transfer of protein was confirmed by staining
the membranes with amidoblack. After a one hour block-
ing step in 5% milk powder in Tris-buffered saline (TBS),
membranes were incubated overnight with the rabbit
polyclonal antiserum pAb (3 F/4) raised against human
TNW (1:750), the mouse monoclonal antibody B28-13
raised against human TNC (1:100), the V-9131 mouse
monoclonal antibody against vinculin (1:2000; Sigma).
After incubation for 1 hour with anti-mouse IgG or anti-
rabbit IgG coupled to horseradish peroxidase, blots were
developed using Super Signal (Pierce) for TNC and
TNW and ECL reagent (GE Healthcare) for vinculin fol-
lowed by exposure to Kodak BioMax MR Films.
Immunostaining and quantification
Chromogenic and fluorescent detections were performed
on 9 μm-thick cryosections using the Discovery XT auto-
mated stainer (Ventana Medical Systems) with standard
and customized procedures, respectively. Frozen tissue
slides were dried for 1 hr at room temperature, fixed for




































































Figure 1 Immunoblot analysis of TNW and TNC protein
expression in various healthy human adult organs (A), in
pancreatic carcinomas (B) and in kidney carcinomas (C). Blots
were also probed for vinculin (VCL) to check equal loadings of
protein samples. A) Note the presence of TNC in all but one organ
tested, whereas TNW is undetectable in the majority of organs. The
last two lanes contain 25 ng of purified TNC or TNW, respectively. B)
Extracts from nine pancreatic carcinomas were tested for their TNW
and TNC levels. Note that TNW is expressed in most of the
pancreatic carcinomas tested. C) Extracts of nine kidney carcinomas
were tested for their TNW and TNC expression. TNW was observed
in most of the kidney carcinomas tested.
Brellier et al. BMC Clinical Pathology 2012, 12:14 Page 3 of 10
http://www.biomedcentral.com/1472-6890/12/14the automate. For chromogenic stainings, slides were
first blocked twice for 12 min with the AB Block reagent
(Ventana). They were then incubated for 1 hr at 37°C
with the mouse monoclonal 56O antibody raised against
human TNW (1:1000) [18] or the B28-13 anti-TNC anti-
body (1:1000). They were then treated for 32 min at 37°C
with a biotinylated anti-mouse secondary antibody
(1:200; Jackson Immunoresearch laboratories 715-065-
150) and developed with DAB Map detection kit (Ven-
tana). Counterstainings were obtained with hematoxylin
and bluing reagent (Ventana). For immunofluorescent
stainings, slides were incubated for 1 hour at 37°C with
anti-TNW mAb 56O (1:50), anti-TNC mAb B28-13
(1:50) or anti-CD31 (1:200; M0823, DAKO). They were
then treated for 32 min at 37°C with Alexa Fluor 647
donkey anti-mouse IgG and Alexa Fluor 488 goat anti-
rabbit IgG secondary antibodies (1:200; Invitrogen
A31571 and A11029, respectively), carefully rinsed by
hand and mounted with prolong Gold reagent (Invitro-
gen). Pictures were either acquired with a Mirax Slides-
canner (Zeiss AG, Zurich, Switzerland) using a 20×/0.5
lens (0.2 μm/pixel) and converted into standard TIFF for-
mat or with a Nikon Eclipse 80i microscope equipped
with a Leica DFC420 color camera. For quantification,
the area of the section stained by TNW or TNC was
measured using ImageJ by setting the color threshold as
follows: hue 0–40, saturation 50–255, luminosity 0–200.
The resulting area was divided by the total area of the
section to obtain a percentage. The samples were then
classified in four categories according to the amount of
staining: 0%, no staining; 1%-10%, low; 11%-40%, moder-
ate; >40%, high. In order to compare tumor type or grade
with the tenascin stainings a numerical score was
assigned to each category (no staining = 0, low = 1, mod-
erate = 2, and high = 3) and the average scores for each
tumor type/grade was calculated.
Results
TNW is not detectable in most adult organs
To compare TNW and TNC protein expression in
healthy adult humans, we analyzed tissue extracts from
ten different organs and analyzed their protein content
on western-blots (Figure 1A). In spleen and liver extracts
very faint bands for TNW were observed. In agreement
with our recent observations, we did not detect any
TNW in healthy human breast, colon and brain tissues
[17-19]. Furthermore, normal uterus, lung, heart, pan-
creas and kidney appeared devoid of TNW, too. In con-
trast, TNC was detectable in all organs tested, except for
normal breast and heart tissues. As has been described
earlier [17-20], we detected different TNC isoforms in
our immunoblot analysis of normal human tissues, al-
though in pancreas, kidney, and colon only the lower
molecular weight TNC isoform was observed.Our earlier studies showed TNW overexpression in
human breast, colon, as well as brain tumors [17-19]. To
obtain a more complete neoplasia-associated expression
profile of TNW, we tested here whether TNW enrich-
ment can also be found in solid tumors originating from
other organs.
TNW is detectable in pancreatic carcinomas
Pancreatic carcinoma extracts from nine different
patients were analyzed by western-blotting for their
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healthy pancreas tissue (Figure 1A), most pancreatic car-
cinomas (7/9) did express detectable amounts of TNW.
Among the seven TNW positive tumors, four contained
very high levels of TNW, as shown by the high intensity
of the corresponding bands (patients # 1, 2, 5, and 6),
and three samples displayed moderate levels (patients #
7–9). According to the intensity of the western-blot
bands, TNC was observed in most of the samples vary-
ing from barely detectable (patients # 1, 7–9) to inter-
mediate (patients # 4, 5) and to high levels (patient # 2,
6). The levels of TNW and TNC did not correlate and
in the sample from patient #1 with the highest TNW
level TNC was barely detectable (Figure 1B). While in
normal pancreas tissue only a low molecular weight iso-
form of TNC was detectable (Figure 1A), pancreas
tumor tissues expressed additional higher molecular
weight isoforms (Figure 1B). So far we do not have any
evidence for the existence of TNW splice-variants
(Figure 1).
TNW is detectable in kidney tumors
TNW and TNC expression was analyzed by western-
blotting in kidney carcinoma samples, and their amounts
were estimated by the intensity of the corresponding
bands (Figure 1C). TNW was detected in most cases
(6/9): 2 out of 9 expressed very high levels of TNW, 4
intermediate levels and in 3 samples TNW was not de-
tectable. TNC was also observed in most samples (7/9),
but again could not be correlated with TNW expression.
In parallel, a frozen kidney tumor TMA (n= 84) was
stained by immunohistochemistry for expression of
TNW and TNC. For each tumor sample, we quantified
expression levels of both tenascins and classified them
into the following 4 categories with respect to their
tenascin expression: absent, low, moderate and high, as
described in Materials and Methods (Figure 2A,B). Al-
though we could not detect TNW by western-blot in
healthy kidney tissue (Figure 1A), immunohistochemical
analysis revealed slight, but clearly visible expression of
TNW in most of the control kidney samples while the
remaining samples were unstained (see representative
image in Figure 2C). As can be seen in the pie chart
more than half of the tumors (56%) expressed moderate
or high levels of TNW while for TNC this was the case
for 92% of all kidney tumors on the TMA (Figure 3A).
Interestingly, TNW was never in a higher expression cat-
egory than TNC (Figure 2B). Using a numerical score
for each category (see Materials and methods) the aver-
age scores for each tumor type was calculated. The aver-
age scores for the levels of TNW and TNC of the 70
clear cell carcinomas were 1.7 ± 0.10 and 2.69 ± 0.07 re-
spectively, for the 6 papillary carcinomas 1.33 ± 0.33 and
2.67 ± 0.33, for the 6 chromophobe carcinomas1.17 ± 0.31 and 2 ± 0.26 and for the 2 oncocytoma 1 and
1. This suggests that the tenascin levels may correlate
with the tumor type. However, more samples would be
necessary to strictly prove such a correlation.
TNW is overexpressed in melanomas
A frozen TMA containing 34 melanoma samples includ-
ing primary tumors and metastases was stained by
immunohistochemistry for TNW and TNC. Each indi-
vidual tumor staining was quantified and categorized as
described above (Figure 3). Representative pictures for
each TNW group for each type of sample are shown in
parallel to the matching TNC stainings of the same
tumor patient. Figure 3A shows stainings of primary
tumors (PT), Figure 3B metastases (MET) and Figure 3C
lymph node metastases (LN-MET). These tumor sam-
ples can be compared to the healthy skin tissue shown
in Figure 3E. TNW was not detectable in any normal
skin sample whereas TNC was observed in the dermis of
three out of six samples (Figure 3D), just below the base-
ment membrane underlying the basal epidermal cell
layer, as has been described previously [21]. A summary
of all stainings is presented in a table (Figure 3D). It
shows that 60% (3 out of 5) of primary melanomas (PT)
had moderate or high expression of TNW, while TNC
was detectable in all of the primary tumor samples with
a staining classified at least as moderate. In samples
obtained from metastasis from diverse locations (i.e.
spleen, lung, skin), TNW had moderate staining in 25%
(2 out of 8) of the samples, while TNC is strongly
expressed in 87% (7 out of 8) of samples. Similar propor-
tions were observed in samples of lymph node metasta-
sis: 38% of samples (8 out of 21) showed moderate or
high TNW, while 71% (15 out of 21) of the samples dis-
played at least moderate TNC staining. Similar to the
kidney TMA analysis, TNW expression was never found
in a higher expression category than TNC. It is note-
worthy that the only two samples in which TNW is clas-
sified in the highest category of expression are both
lymph node metastases.
TNW is overexpressed in lung tumors
In our analysis of lung tumors we stained a total of 95
tumor samples for the presence of TNW and TNC.
Immunohistochemical analysis showed that TNW was
detectable in all 95 tumor samples (Figure 4). For 21 of
these samples we were able to analyze matching adjacent
normal lung parenchyma that had been biopsied at least
3 cm away from the edge of the tumor. These corre-
sponding healthy tissues did not display any detectable
TNW expression demonstrating that TNW expression
was restricted to tumor associated stroma. In contrast,
TNC was also present in the normal lung tissue adjacent
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7 30 35 12
high 581 17 28 12
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Figure 2 Immunohistochemical analysis of kidney tumor
samples. Eighty-four kidney tumor samples, spotted on a frozen
TMA were stained for expression of TNW and TNC. The area of the
section stained for TNW or TNC was quantified and the samples
were classified in four categories (absent, low, moderate and high)
as described in Materials and Methods. The number of tumors
classified in each category for TNW and TNC is shown as pie charts
(A). A double-entry table details how many tumors show each
combination of TNW/TNC expression (B). Top panel in C shows
normal kidney tissues stained for TNW (left) and TNC (right).
Representative pictures of tumors of each category (absent; low;
moderate; high) are shown for TNW (C, left panel) with the
corresponding tumor area stained for TNC in parallel (C, right panel).
Every picture is acquired at the same magnification (Scale
bar = 200 μm).
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a fibrous staining (parallel lines forming bundles) sur-
rounding nests of tumor cells (Figure 4C, #9297). This
suggests that TNW is mainly expressed by stromal cells
surrounding the carcinoma cells. Quantification of the
stained area of tumors from an extended cohort of
patients (n = 95) revealed that TNW expression was
never completely absent in any of the tumors, a feature
shared by TNC (Figure 4A,B). 65% of the tumor samples
had at least moderate TNW expression while for TNC
this was the case for 92% of the samples. With the ex-
ception of 5 cases, TNC was in the same or higher ex-
pression category as TNW (Figure 4B). However, since
TNC expression levels in control lung tissues have been
much higher than TNW levels, TNW seems to be much
more tumor-specific than TNC in the case of the lung.
Information about the stage of the tumor was available
for 69 of the 95 samples included in the present study.
Interestingly, the average level of TNW seems to correl-
ate with tumor grade: the two grade I tumors both have
a TNW score of 1 (TNC score is 2); grade II tumors
(n = 19) have an average TNW score of 1.74 ± 0.15
(TNC: 2.47 ± 0.18); tumors with grade intermediate be-
tween II and III (n = 6) have an average score of
1.83 ± 0.30 (TNC: 2.33 ± 0.33); grade III tumors (n = 27)
have average score of 2.18 ± 0.17 (TNC: 2.55 ± 0.11); fi-
nally, the average TNW score of grade IV tumors
(n = 15) is 2.07 ± 0.23 (TNC: 2.6 ± 0.16). Although the
number of samples examined is too small to draw statis-
tically significant conclusions, there seems to be a ten-
dency for increased TNW expression in higher grade
tumors.
TNW is expressed around blood vessels
Our previous study on TNW expression in brain tumors
showed for the first time that TNW is expressed around
blood vessels of gliomas [19]. Here, we investigated
whether this observation holds true as well for tumors













































Figure 3 Immunohistochemical analysis of melanoma samples. Thirty-four melanoma tissues from a frozen TMA were stained for their
expression of TNW and TNC. The area of the section stained for TNW or TNC was quantified and the samples were classified as in Figure 2.
Representative pictures of each tumor type are grouped in different panels: A) primary tumors (PT), B) metastases (MET), C) lymph node
metastases (LN-MET). From top to bottom, pictures in the left column of each panel represent increasing scores of TNW from absent, low,
moderate to high (only in panel C) with the corresponding tumor stained for TNC in the right column of each panel. Panel E shows normal skin
tissue stained for TNW (left) and TNC (right). Every picture is acquired at the same magnification (Scale bar = 200 μm). Table D summarizes the
distribution of the scores for each tenascin in the different groups.
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an established blood vessel marker (Figure 5). In most of
the tumor samples a prominent co-localization between
TNW and blood vessels (CD31 positive) was observed.
These results confirmed our earlier study in brain
tumors and suggest that TNW is often expressed adja-
cent to blood vessels, independently of vessel size. TNW
co-localization with blood vessels was also observed in
additional analyses of colon, breast, ovarian and prostate
tumors (data not shown). Thus, the presence of TNW
around tumor blood vessels seems to be widespread.
Discussion
Recent studies on TNW have identified this protein as a
candidate biomarker for breast tumors [17], colorectal
tumors [18] as well as gliomas [19]. In addition to these
tumor sites, we report in the present study that TNW is
also prominently expressed in melanomas, pancreas, kid-
ney and lung carcinoma samples. Importantly, we werenot able to detect it in the normal corresponding organs,
except for a slight presence in normal kidney. The
tumor-specific expression was especially striking for the
lung for which we had clinical material available to com-
pare 21 tumors with matching healthy tissue fragments
of the same patient. All of these 21 tumor/non-tumor
pairs revealed a specific tumor-restricted TNW staining,
whereas the non-tumor samples were all negative. There-
fore, TNW might be a diagnostic marker for lung cancer
and its expression seems to increase with tumor grade.
TNW was also expressed in the majority of kidney
tumors tested. Although western-blot analysis did not re-
veal the presence of TNW in a kidney control tissue ex-
tract, we could observe a slight TNW staining by
immunohistochemistry in all 10 control kidney tissues
analyzed. This result is in agreement with our previous
observation that TNW can be found in the kidney of
adult mice [22]. TNW and TNC levels appeared on aver-
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0 33 36 26
high 510 10 20 21
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Figure 4 Immunohistochemical analysis of lung tumor samples. Ninety-five lung tumor sections were stained for their expression of TNC
and TNW and classified as described in Figure 2. The number of tumors classified in each category for TNC and TNW is shown as pie charts (A). A
double-entry table details how many tumors show each combination of TNW/TNC expression (B). Twenty-one pairs of matching lung normal/
tumor lung tissue samples were stained for their expression of TNW and TNC. Representative stainings are shown: From top to bottom, tumor
pictures represent increasing scores of TNW from low, moderate to high with the corresponding tissues stained for TNC in the right panels. From
top to bottom an adenocarcinoma, a squamous carcinoma and an undifferentiated carcinoma are shown (C). Every picture is acquired at the
same magnification (Scale bar = 200 μm).
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oncocytoma, suggesting a correlation with severity of the
disease. In addition, we could also observe overexpres-
sion of TNW in ovarian cancer samples and in prostate
tumors (data not shown). Our general observation that
TNW is overexpressed in the stroma surrounding many
tumors, but absent in most corresponding control tis-
sues, qualifies TNW as a tumor biomarker. This is less
the case for TNC, as TNC overexpression has been cor-
related with various conditions other than cancers, such
as inflammation, infection, asthma, fibrosis and wound
healing (for reviews see [7,8]).
So far, TNW overexpression has been exclusively
described in the context of tumorigenesis andosteogenesis [6], which suggests that it might be a more
specific tumor marker than TNC. However, in the case
of TNC certain splice variants with additional fibronec-
tin type 3 domains have been shown to be more tumor-
specific than the shortest isoform [23,24]. Therefore,
isoforms-specific antibodies against TNC can also be
used as tumor-specific markers [24,25]. This is also the
case for another ubiquitous extracellular matrix protein,
namely fibronectin, which was shown to have cancer-
specific splice variants which can be used as targets for
antibody-mediated therapy in human patients [26,27].
We can not exclude so far a possible association be-
tween TNW and other types of tissue remodeling condi-
tions such as inflammation or wound healing. However,
Figure 5 Double immunofluorescence staining of TNW and CD31 in kidney tumors (upper panel) and lung tumors (lower panels).
Tumor cryosections were used for fluorescent detection of TNW (red), CD31 (green) and DAPI (blue). Each row represents a different tumor
sample. Scale bars = 50 μm.
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patients with inflammatory bowel diseases (even in areas
where TNC is highly expressed – our unpublished data),
nor in wound healing in the mouse [28]. It remains to
be seen whether TNW is elevated in sera of patients suf-
fering from solid tumors other than breast and colon,where elevated TNW serum levels have been described
[18]. The same might be the case for pancreas, kidney or
lung tumor patients as these tumors show strong TNW
staining in situ.
Here we have found that TNW is expressed in close
vicinity of blood vessels in a wide range of tumors
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tumors. In another study we have found that TNW acts
as a pro-angiogenic factor in vitro [19]. Therefore, we
can speculate that in vivo TNW could act on tumor
endothelial cells, influencing their migration and thus
contributing to the expansion of the endothelial net-
work. What triggers TNW expression in the tumor
stroma and more particularly next to the blood vessels
remains to be established, but it likely involves complex
tumor-microenvironment interactions. Interestingly, a
similar deposition outside the endothelial basement
membrane has already been described for large TNC
splice variants in newly formed blood vessels [23,29].
Use of a renal carcinoma xenograft model has revealed
that the source of these perivascular large TNC mole-
cules were the carcinoma cells themselves [29]. It would
be of high interest to establish whether carcinoma cells
could also be the source of blood vessels associated
TNW.
In several tumors, there is now compelling evidence
that the capacity for a tumor to grow and proliferate lies
in a small fraction of cells, called cancer stem cells
(CSC) or cancer initiating cells [30]. Similar to normal
stem cells, CSC have the ability to self-renew and to dif-
ferentiate into a variety of proliferating cells that make
up the tumor mass. It can be speculated that mainten-
ance of CSCs depends upon a specific stem cell niche
microenvironment that protects CSCs from therapeutics.
Therefore, targeting these microenvironments might re-
sult in more effective treatments of cancers. Interest-
ingly, TNC has been reported to maintain an ABCB5+
subpopulations of melanoma-initiating cells thereby pro-
moting melanoma progression [31]. Moreover, for sev-
eral cancers, cancer stem cell populations reside in
perivascular niches as their preferred microenvironment
[32-35]. Given the tumor-specific overexpression of
TNW and its perivascular staining pattern, one can
speculate about a role for TNW in maintaining CSC’s
and offering them a congenial niche.
Conclusions
The present study extends the potential of TNW as can-
cer biomarker to a large variety of solid tumors. Given
both its specific expression in tumors compared to cor-
responding healthy tissues and its proximity to tumor
blood vessels (making it accessible via the bloodstream)
we propose TNW as a good candidate for selective deliv-
ery of anticancer medicine. The perivascular deposition
pattern of TNW however will limit this strategy to
antibody-drug conjugates able to cross the blood vessel
walls.
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